梅花生物(600873) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 reached ¥6,601,538,523.32, a 25.55% increase compared to ¥5,258,021,313.79 in the same period last year[4] - Net profit attributable to shareholders was ¥868,244,074.94, representing a 168.95% increase from ¥322,829,844.65 year-on-year[4] - Net profit excluding non-recurring gains and losses was ¥854,513,403.83, up 185.29% from ¥299,523,886.60 in the previous year[4] - Basic earnings per share for Q3 2022 was ¥0.28, a 180.00% increase from ¥0.10 in the same quarter last year[4] - Diluted earnings per share also stood at ¥0.28, reflecting a 180.00% increase compared to ¥0.10 year-on-year[4] - The weighted average return on equity increased to 6.98%, up 3.53 percentage points from 3.45% in the previous year[4] - The company achieved operating revenue of 6.602 billion RMB in Q3 2022, an increase of 25.55% year-on-year, primarily due to a 30.46% increase in revenue from animal nutrition amino acid products and a 23.66% increase from food flavor optimization products[7] - Net profit attributable to shareholders reached 868 million RMB, a significant increase of 168.95% compared to the same period last year, driven by improved gross margin from 14.9% to 21.79%[7] - The net profit excluding non-recurring items was 855 million RMB, reflecting a year-on-year increase of 185.29% due to substantial growth in net profit[7] - For the first three quarters of 2022, the company reported operating revenue of 20.821 billion RMB, up 27.86% year-on-year, with animal nutrition amino acid products increasing by 34.05%[7] - The net profit attributable to shareholders for the first three quarters was 3.444 billion RMB, an increase of 159.49% year-on-year, with gross margin improving from 17% to 25.33%[7] - Operating profit for the first three quarters was ¥4.01 billion, up from ¥1.60 billion in the same period last year, marking an increase of 150.5%[14] - Earnings per share (EPS) for the first three quarters was ¥1.11, significantly higher than ¥0.43 in the same period last year[15] Cash Flow and Assets - Operating cash flow for the year-to-date period was ¥5,455,580,471.51, a 66.46% increase from ¥3,277,319,871.83 last year[4] - The net cash inflow from operating activities was CNY 5,455,580,471.51, an increase of 66.7% compared to CNY 3,277,319,871.83 in the previous year[16] - Total cash inflow from operating activities amounted to CNY 22,997,408,878.67, up from CNY 16,781,349,140.49, reflecting a growth of 37.5%[16] - Cash outflow for purchasing goods and services was CNY 14,578,608,257.55, compared to CNY 11,608,702,273.41, representing a 25.5% increase[16] - Cash flow from operating activities was ¥22.53 billion, compared to ¥16.52 billion in the same period of 2021, representing a growth of 36.4%[15] - Total current assets increased to ¥8,798,777,198.90 from ¥7,570,836,910.82 as of December 31, 2021, representing a growth of approximately 16.2%[11] - Cash and cash equivalents decreased slightly to ¥3,372,690,209.53 from ¥3,396,202,312.57, a decline of about 0.7%[11] - Accounts receivable rose significantly to ¥373,336,140.56, up from ¥280,597,054.53, marking an increase of approximately 33.1%[11] - Inventory decreased to ¥2,688,212,029.89 from ¥2,992,013,893.38, reflecting a decline of about 10.2%[11] - Total non-current assets increased marginally to ¥13,418,030,948.34 from ¥13,408,613,651.93, showing a growth of approximately 0.1%[12] - Total assets at the end of the reporting period were ¥20,921,200,513.89, a 5.90% increase from ¥22,216,808,147.24 at the end of the previous year[4] Shareholder Information - The company has a total of 95,983 common shareholders as of the end of the reporting period[9] - The largest shareholder, Meng Qingshan, holds 28.07% of the shares, with 854,103,033 shares pledged[9] Expenses and Financial Management - Research and development expenses amounted to ¥198.83 million, slightly up from ¥191.23 million in the previous year, indicating a focus on innovation[14] - Total operating costs increased to ¥16.88 billion, up from ¥14.72 billion, reflecting a rise of 14.7%[14] - The company reported a decrease in financial expenses to ¥53.27 million from ¥140.14 million, indicating improved financial management[14] - The gross profit margin improved, with gross profit reaching ¥4.94 billion, compared to ¥1.56 billion in the previous year[14] - The company experienced a net foreign exchange loss of ¥1.03 million, compared to a loss of ¥748,061.48 in the previous year, indicating a slight improvement in currency management[15] Tax and Employee Payments - The company received tax refunds amounting to CNY 388,233,192.16, compared to CNY 216,507,438.28, which is an increase of 79.3%[16] - Cash paid to employees was CNY 1,021,173,581.78, an increase from CNY 875,837,850.44, representing a growth of 16.6%[16] - The cash outflow for taxes paid was CNY 1,033,536,331.87, significantly higher than CNY 505,071,878.91, indicating a rise of 104.5%[16] Strategic Developments - The company has not reported any significant new strategies or product developments in the current quarter[10]